In a 15 year follow-up of a pilot Phase III trial of Stage II breast cancer patients treated with oxidized mannan linked to MUC1 with 5 TR, the recurrence rate was greatly reduced compared to placebo (two out of 16 patients versus nine out of 15 patients) [20]. This evidence concerns the gene MUC1 and breast cancer.